褪黑素能激动剂预防ICU谵妄的有效性与安全性:随机对照试验的更新剂量-反应Meta分析
该更新剂量-反应Meta分析纳入24项随机对照试验共3680例ICU患者,评估褪黑素或雷美替胺预防谵妄的效果。与安慰剂相比,褪黑素能激动剂降低谵妄发生率(RR 0.77 [0.62,0.94]),褪黑素组(RR 0.77 [0.62,0.97])和外科型ICU(RR 0.64 [0.48,0.87])效果更优。累积剂量与谵妄风险呈非线性剂量-反应关系,最佳累积剂量为22 mg褪黑素(RR 0.732 [0.599,0.895]);干预≥7天组效果更优(RR 0.73 [0.60,0.90])。对28-30天死亡率、ICU死亡率及不良事件发生率无影响,ICU住院时间、机械通气时间有临床相关趋势但未达统计学显著。作者认为褪黑素能激动剂可能降低ICU谵妄风险,尤其适用于褪黑素组、外科型ICU及干预≥7天者,但效应量中等、证据确定性低、异质性中等,需谨慎解读。
要点
- 与安慰剂相比,褪黑素能激动剂降低ICU谵妄发生率(RR 0.77 [0.62,0.94],18项研究主要分析)。
- 褪黑素组谵妄风险降低(RR 0.77 [0.62,0.97]),外科型ICU降幅更大(RR 0.64 [0.48,0.87])。
- 累积剂量与谵妄风险呈非线性剂量-反应关系,最佳累积剂量为22 mg褪黑素(RR 0.732 [0.599,0.895])。
- 干预≥7天亚组谵妄风险降低更优(RR 0.73 [0.60,0.90])。
- 对28-30天死亡率、ICU死亡率及不良事件无影响;ICU住院时间和机械通气时间有临床相关趋势但未达统计学显著。
适用人群与场景
- ICU患者,纳入24项随机对照试验共3680例参与者。
- 亚组分析包括褪黑素组和外科型ICU患者。
处置流程与药物剂量
- 褪黑素或雷美替胺用于预防ICU谵妄;最佳累积剂量为22 mg褪黑素(基于剂量-反应分析)。
- 干预持续时间≥7天的亚组效果更优(RR 0.73 [0.60,0.90])。
研究设计与关键结果
- 研究类型:随机对照试验的更新剂量-反应Meta分析,共纳入24项研究、3680例参与者。
- 主要分析(18项研究):与安慰剂相比,褪黑素能激动剂降低谵妄发生率(RR 0.77 [0.62,0.94])。
- 亚组:褪黑素组RR 0.77 [0.62,0.97];外科型ICU RR 0.64 [0.48,0.87]。
- 剂量-反应:累积剂量与谵妄风险呈非线性关系,最佳累积剂量22 mg褪黑素(RR 0.732 [0.599,0.895])。
- 干预时长:≥7天亚组RR 0.73 [0.60,0.90],干预时长对谵妄风险有显著影响。
- 死亡率与安全性:对28-30天死亡率、ICU死亡率及不良事件发生率无影响。
- 次要结局:ICU住院时间(MD -0.74 [-1.60, 0.12])、医院住院时间(MD -0.33 [-1.91, 1.25])、机械通气时间(MD -0.50 [-1.16, 0.16])有基于最小临床重要差异的临床相关趋势但未达统计学显著;谵妄发作时间可能延长(MD 0.76 [0.43, 1.09]),证据确定性极低。
证据类型、等级与局限
- 证据类型:随机对照试验的剂量-反应Meta分析,采用GRADE评估证据确定性,ICEMAN工具评估亚组分析可信度。
- 证据确定性低,异质性中等。
- 局限:效应量中等,证据确定性低,异质性中等,需谨慎解读。
对床旁实践的改变
- 作者认为褪黑素能激动剂可能降低ICU患者谵妄风险,尤其适用于褪黑素组、外科型ICU及干预持续时间≥7天者,最佳累积剂量为22 mg褪黑素。
- 作者认为褪黑素能激动剂似乎安全,并可能有助于缩短ICU住院时间和机械通气时间。
- 作者指出效应量中等、证据确定性低、异质性中等,需谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Melatonin (MEL) modulates the circadian rhythm and has been studied as a preventive measure against delirium, especially in intensive care unit (ICU) patients, but the current findings are conflicting. We performed a pairwise dose‒response meta-analysis of randomized controlled trials (RCTs) followed by meta-regression and trial sequential analysis to assess the ability of MEL or ramelteon (RAL) to prevent delirium in the ICU. We evaluated the certainty of the evidence via GRADE and the credibility of the subgroup analysis via the ICEMAN tool. We identified 24 studies that included 3680 participants. Compared with placebo, melatoninergic agonists reduce the incidence of delirium (0.77 [0.62,0.94], primary analysis of 18 studies), with superior effects in the MEL group (RR 0.77 [0.62, 0.97]) and in surgical-type ICU (RR 0.64 [0.48, 0.87]). We found a nonlinear dose‒response relationship between the cumulative dose of MEL and the RR of delirium, suggesting an optimal cumulative dose of 22 mg of MEL (RR 0.732 [0.599, 0.895]). Subgroup and meta-regression analyses revealed a significant effect of intervention duration on the risk of delirium, with a superior effect in the subgroup with ≥ 7 days of intervention (RR 0.73 [0.60, 0.90]). Melatoninergic agonists did not affect 28-30-day or ICU mortality or the incidence of adverse effects. Melatoninergic agonists showed a clinically relevant trend based on the minimal clinically important difference (MCID) to reduce the ICU length of stay (LOS) (MD:-0.74 [-1.60, 0.12], MCDI -0.113 [1.846, -2.073]), hospital LOS (MD -0.33 [-1.91, 1.25], MCID -0.134 [1.833, -2.108]) and length of mechanical ventilation (MV) (MD -0.50 [-1.16, 0.16], MCID -0.2146 [1.744, -2.173]). Compared with placebo, they may increase the time to the onset of delirium (MD 0.76 [0.43, 1.09]), but with very-low certainty. Our findings indicate that melatoninergic agonists probably reduce the risk of delirium in ICU patients, especially those treated with MEL, in surgical-type ICUs and for durations equal to or longer than 7 days, with an optimal cumulative dose of 22 mg. Additionally, they appear to be safe while offering potential benefits in reducing ICU length of stay and duration of mechanical ventilation. However, the magnitude of effect was modest, with low-certainty evidence and moderate heterogeneity, and these findings should therefore be interpreted with caution.
参考来源
- Chaves-Filho A, Medrado MF, Zamboni T, et al. Effectiveness and safety of melatoninergic agonists in preventing delirium in the ICU: an updated dose‒response meta-analysis of randomized controlled trials. Crit Care. 2026. PMID: 42310686. doi:10.1186/s13054-026-06047-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。